RNAC — Cartesian Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $480.67m
- $377.25m
- $26.00m
Annual cashflow statement for Cartesian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -55.4 | -68.9 | -25.7 | 35.4 | -220 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.67 | 18 | 12.2 | -7.92 | 182 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.48 | 85 | -48.2 | -60.4 | 4.97 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -51.4 | 34.9 | -60.4 | -31.6 | -51.2 |
| Capital Expenditures | -0.047 | -0.815 | -1.08 | -1.2 | -0.206 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.276 | 0.074 | -16.1 | -13.8 | 34.8 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.229 | -0.741 | -17.1 | -15 | 34.6 |
| Financing Cash Flow Items | — | -4.72 | 0 | -0.11 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 105 | 14.4 | 52.9 | 39.2 | -13.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 53.9 | 48.5 | -24.6 | -7.4 | -29.8 |